
IQVIA Holdings Inc.
IQVNYSEHealthcareMedical - Diagnostics & Research
Previous close
$259.82
+$3.77 · +1.47%
IQV company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
90
Deep Value
Momentum
52
Neutral
Sentiment
69
Bullish
Risk resilience
57
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteIQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Ari Bousbib
- Listed since
- May 9, 2013
- Employees
- 94,000
Market position
Day range
Current $259.82
52-week range
Current $259.82
- Open
- $256.79
- Previous close
- $256.05
- Volume
- 1.14M
- 0.72× average
- Average volume
- 1.58M
- Average daily volume
- Market cap
- 42.77B USD
- Beta
- 1.18
- Market reference 1
- 50-day average
- $212.96
- +22.00% above average
- 200-day average
- $199.52
- +30.22% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 52.94B USD
- P/E (TTM)
- 31.96×
- P/B (TTM)
- 7.04×
- P/S (TTM)
- 2.52×
- EV / EBITDA
- 15.28×
- Earnings yield
- 3.51%
- Free cash flow yield
- 5.29%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 26.23%
- Operating margin
- 13.57%
- Net margin
- 8.10%
- Return on equity
- 20.91%
- Return on assets
- 4.54%
- Return on invested capital
- 8.23%
Financial health
- Debt / equity
- 2.63×
- Current ratio
- 0.75×
- Altman Z-score
- 2.18
- Piotroski F-score
- 7 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 16.31B USD | 15.41B USD | 14.98B USD | 14.41B USD | 13.87B USD |
| Cost of goods sold | 12.02B USD | 10.03B USD | 9.75B USD | 9.38B USD | 9.23B USD |
| Gross profit | 4.29B USD | 5.38B USD | 5.24B USD | 5.03B USD | 4.64B USD |
| Selling, general, and administrative | 2B USD | 1.99B USD | 2.05B USD | 2.07B USD | 1.96B USD |
| Operating expenses | 2B USD | 3.17B USD | 3.26B USD | 3.23B USD | 3.25B USD |
| Interest income | 45M USD | 47M USD | 36M USD | 13M USD | 6M USD |
| Interest expense | 729M USD | 670M USD | 672M USD | 416M USD | 375M USD |
| Depreciation and amortization | 1.14B USD | 1.11B USD | 1.13B USD | 1.13B USD | 1.26B USD |
| Operating income | 2.29B USD | 2.2B USD | 1.98B USD | 1.8B USD | 1.39B USD |
| Net income | 1.36B USD | 1.37B USD | 1.36B USD | 1.09B USD | 966M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 100%
- 11 beats, 0 misses, 0 met estimates
- Average EPS surprise
- +1.73%
- 11 comparable reports
- Latest EPS result
- 3.15
- Estimate 3.03 · Beat by 3.96%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$237.38
8.64% downsideRating distribution
45 ratingsRecent analyst actions
IQV news
IQV peers
ETFs holding IQV
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.25B0.05%2.3T USD0.03%$378.24+0.44%
Vanguard S&P 500 ETFVOO1.03B0.06%1.7T USD0.03%$703.71+0.39%
Vanguard Morningstar Mid-Cap ETFVO848.91M0.38%224.7B USD0.03%$82.97+0.53%
iShares Core S&P 500 ETFIVV576M0.06%891.84B USD0.03%$769.31+0.39%
State Street SPDR S&P 500 ETFSPY531.57M0.06%817.87B USD0.09%$765.72+0.41%
Vanguard Morningstar Value ETFVTV373.71M0.15%256.5B USD0.03%$226.4+0.54%
State Street Health Care Select Sector SPDR ETFXLV307.4M0.69%44.76B USD0.08%$174.62+1.29%
Invesco S&P 500 Equal Weight ETFRSP262.46M0.26%100.27B USD0.20%$221.67+0.63%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 1.25B
- Weight
- 0.05%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard S&P 500 ETFVOO- Market value
- 1.03B
- Weight
- 0.06%
- AUM
- 1.7T USD
- Expense ratio
- 0.03%
- Price / 1D
- $703.71+0.39%
Vanguard Morningstar Mid-Cap ETFVO- Market value
- 848.91M
- Weight
- 0.38%
- AUM
- 224.7B USD
- Expense ratio
- 0.03%
- Price / 1D
- $82.97+0.53%
iShares Core S&P 500 ETFIVV- Market value
- 576M
- Weight
- 0.06%
- AUM
- 891.84B USD
- Expense ratio
- 0.03%
- Price / 1D
- $769.31+0.39%
State Street SPDR S&P 500 ETFSPY- Market value
- 531.57M
- Weight
- 0.06%
- AUM
- 817.87B USD
- Expense ratio
- 0.09%
- Price / 1D
- $765.72+0.41%
Vanguard Morningstar Value ETFVTV- Market value
- 373.71M
- Weight
- 0.15%
- AUM
- 256.5B USD
- Expense ratio
- 0.03%
- Price / 1D
- $226.4+0.54%
State Street Health Care Select Sector SPDR ETFXLV- Market value
- 307.4M
- Weight
- 0.69%
- AUM
- 44.76B USD
- Expense ratio
- 0.08%
- Price / 1D
- $174.62+1.29%
Invesco S&P 500 Equal Weight ETFRSP- Market value
- 262.46M
- Weight
- 0.26%
- AUM
- 100.27B USD
- Expense ratio
- 0.20%
- Price / 1D
- $221.67+0.63%
Continue in GoAI
Research IQVresearch.disclaimer











